# Study of the Vascular Effects of Serelaxin

> **NCT01979614** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 58 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Serelaxin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01979614
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-03
- **Primary completion:** 2016-08-17
- **Final completion:** 2016-08-17
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2019-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01979614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01979614, "Study of the Vascular Effects of Serelaxin". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01979614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*